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The generation of well-characterized parts and the formulation of biological design principles in synthetic biology are laying the
foundationformorecomplexandadvancedmicrobialmetabolicengineering.ImprovementsindenovoDNAsynthesisandcodon-
optimization alone are already contributing to the manufacturing of pathway enzymes with improved or novel function. Further
development of analytical and computer-aided design tools should accelerate the forward engineering of precisely regulated
synthetic pathways by providing a standard framework for the predictable design of biological systems from well-characterized
parts. In this review we discuss the current state of synthetic biology within a four-stage framework (design, modeling, synthesis,
analysis) and highlight areas requiring further advancement to facilitate true engineering of synthetic microbial metabolism.
1.Introduction
As with its sister ﬁeld of systems biology, synthetic biology is
perhaps best described not by what you do, but how you do
it. From this perspective, one way of summarizing synthetic
biology is by its intended goal of making biological systems
explicitly tractable through careful modularization of biol-
ogy [1]. In this vein, the core emphases in synthetic biology
are synthesis, abstraction, and standardization of biological
components [2]. Synthesis refers to the generation of modu-
lar, reusable biological parts (normally as DNA). Abstraction
referstotheimplementationofsynthesizedpartsbyfunction
rather than composition (e.g., “this is a promoter” rather
than “this is ttgacagctagctcagtcctaggtataatgctagc”) and can
facilitate the design of more complex biological devices and
systems. One of the hallmarks of this approach is the push
for standardization where all synthesized parts and devices
are characterized, reproducible, and interchangeable.
Although nascent, the approach employed in synthetic
biology is already making signiﬁcant contributions in areas
within biological engineering and basic biological research
by providing a rigorous framework for building biological
systems from the ground-up [3]. Progress in synthetic biol-
ogy is providing the concepts and tools to develop biological
engineering as an application of biology, just as chemical
engineering is an application of chemistry. Although the
scope of applied synthetic biology is wide, including areas
that are “beyond the bioreactor” such as bioremediation,
agriculture, and human health [4], it is apparent that many
of the applications of synthetic biology that will materialize
in the near future are in metabolic engineering [5]. In this
context, the synthetic biology approach aims to generate
scalable, reusable genetic parts for controlling genetically
encodedunitoperations(e.g.,enzymes,transporters),forthe
predictable design and construction of metabolic pathways
[6].
Since its inception, made possible by the advent of
recombinant DNA technology and the polymerase chain
reaction (PCR), the goal of metabolic engineering has been
to optimize cellular metabolism for a particular process
application—often through extensive genetic modiﬁcation.
While research in metabolic engineering has continued
to advance with a growing number of genetic, analytical,
and computational tools [7], the application of synthetic
biology to metabolic engineering has the potential to create
a paradigm shift [8]. Rather than starting with the full
complement of components in a wild-type organism and
piecewisemodifyingandstreamliningitsfunction,metabolic2 Journal of Biomedicine and Biotechnology
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Figure 1: Synthetic biology four-step engineering workﬂow. The
design and modeling steps (white text) are computational in
nature, whereas the synthesis and analysis steps (black text) are
experimentally-based. The workﬂow presents the relationships
between the individual steps as well as a logical progression using
a synthetic biology framework to generate a product that meets
determined speciﬁcations.
engineeringcanbeattemptedfromabottom-up,parts-based
approach to design by carefully and rationally specifying
the inclusion of each necessary component. In this way, the
metabolic engineering process becomes uniform for any goal
and eliminates laborious cycles of trial and error.
In this review, we discuss synthetic biology as it applies
speciﬁcally to metabolic engineering applications. For the
purposes of this discussion, we are presenting the typical
workﬂow of synthetic biology within a four step framework
(Figure 1). As depicted in the ﬂow diagram, the typical stages
involved are: design, modeling, synthesis, and analysis. The
workﬂow is often highly cyclical, although progress is being
made on moving from iterative biological design to more
predictable, directed design. In the following sections, we
discuss recent progress and current challenges in applying
synthetic biology to metabolic engineering for each of the
four workﬂow steps (design, modeling, synthesis, and anal-
ysis) in general and speciﬁcally at the level of genetic parts
and metabolic pathways. While synthetic biology applies to
all levels of biological organization, we are delineating parts
(individual functional units such as promoters, ribosomal
binding sites, protein coding sequences, and terminators)
from pathways (part-based systems) as there are often
diﬀerent considerations or methodologies employed at these
levels.
2.Design
Imagine an architect preparing blueprints for someone’s
dream house. In the design process, the architect will
largely focus on including all of the desired functional
and aesthetic components but there will also need to be
some consideration given to standard safety and logistical
requirements. A draft blueprint can be generated to best
satisfy the functional and logistical requirements and after
the design is approved, the materials needed for construc-
tion can be purchased. In this scenario, the design and
construction (synthesis) phases are decoupled due to the
availability of standard, readily available building materials.
Currently, the design and synthesis of biological systems are
not decoupled. For example, the construction of metabolic
pathwaysfromgeneticpartsﬁrstrequiresacollectionofwell-
characterized parts, which do not yet exist. This shortcoming
is beginning to be addressed by the synthetic biology
community through the development and compilation of
standard biological building blocks such as those found
in the Registry of Standard Biological Parts. Although
virtually nonexistent now, the future availability of modular,
functionally interoperable genetic parts that are carefully
characterized will allow biological design to focus more
exclusively on functional, aesthetic, and logistical concerns
independent of construction concerns.
2.1. Parts. In designing individual biological parts, the
base-by-base content of that part (promoter, ribosome-
binding site (RBS), protein coding region, terminator, etc.)
is explicitly dictated. Rules and guidelines for designing
genetic parts at this level are just beginning to be estab-
lished [9]. In particular, a major consideration in designing
protein-coding parts is codon optimization, encoding the
same amino acid sequence with an alternative, preferred
nucleotide sequence. Although a particular sequence, when
expressed,maybetheoreticallyfunctional,itsexpressionmay
be far from optimal or even completely suppressed due to
codon usage bias in the heterologous host [10]. Although
the design principles for expressing exogenous genes have
not been perfected, existing codon optimization strategies
are used routinely to enhance pathway performance. Codon
optimization of coding sequences can be achieved using
freely available algorithms such as Gene Designer, stand-
alone software made by DNA2.0. In addition to codon
optimization, other considerations such as compliance with
standard assembly requirements and part-speciﬁc objectives
including activity or speciﬁcity modiﬁcations are often
considered. For example, the BioBrick methodology requires
that BioBrick parts exclude four standard restriction enzyme
sites, which are reserved for use in assembly [11].
Extensive collections of parts can be generated by using
a naturally occurring part as a template and rationally
modifying it to create a library of that particular genetic
part. Signiﬁcant progress in this area has been recently
demonstrated for promoters and RBSs [12, 13]. The work
by Ellis et al. documents the generation and characterization
of two promoter libraries that can be used to tune network
behavior ap r i o r iby ﬁtting mathematical promoter models
with measured parameters [12]. This model-guided design
approach limits system variability, increasing predictability
and decreasing the time spent on combinatorial system con-
struction, testing and debugging. Noisy or leaky promoters
can complicate system design by adding variability. In these
cases, ﬁner control over expression can be established by
weakening the binding strength of the downstream RBS [14]
or by using two promoter inputs to drive transcription of an
output via a modular AND gate [15].
In addition to increasing the number of parts within
existing families (e.g., constitutive promoters), there is an
opportunity to develop entirely new parts families such as
those used to build RNA devices that can regulate expression
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devices that incorporate RNA aptamers for sensing small
molecules, transmitter sequences that transmit information
by way of a conformational change, and actuators such
as hammerhead ribozymes that may render the mRNA
untranslatable depending on the state of the sensor and
transmitter [17]. The beneﬁt of these devices is that they
are composed of modular parts and are completely scalable,
since RNA aptamers can theoretically be designed to sense
any small molecule ligand [18].
2.2. Pathways. Rational pathway design can be thought
of as mixing and matching well-known, modular parts
and modulating gene expression through various control
mechanisms. One of the primary motivations behind the
attempt to achieve ﬁne control of gene expression in the
context of metabolic engineering is simply to balance and
optimize ﬂux through a desired pathway [19]. Thus, design
at the pathway-level is not only concerned with including
the necessary parts, but also with controlling the expressed
functionality of those parts (e.g., a speciﬁc gene may be used
in diﬀerent pathways, the level of required expression may
diﬀer based upon the context).
Parts-based synthetic metabolic pathways will require
tunable control, just as their natural counterparts which
often employ feedback and feedforward motifs to achieve
complex regulation [20]. The temporal and spatial dynamics
necessary for life (e.g., diﬀusion, evolution, growth/death)
make it diﬃcult to achieve this goal. For example, biological
signals must diﬀuse throughout the cell until it is received
by the signal’s receptor, unlike an electrical signal that is
insulated and directed along a path. Therefore, information
transfer in biological systems is intrinsically noisy, an issue
thathasbeenreviewedandcontinuestobeexplored[21,22].
This is the case for gene regulation at the transcription
level in which there is a DNA-protein interaction between
regulatory proteins such as the LacI repressor and its
operator site, lacO. Although a handful of operator-regulator
pairs have been used successfully to construct simple genetic
circuits [23, 24], more complex networks will likely require
a large repetoire of distinct regulatory elements to eliminate
molecular cross-talk. Developing regulatory parts such as
promoters, operator-regulator pairs, ribosome binding sites
(RBSs), and riboswitches is a proven way to tackle this
problem [25]. Table 1 lists a sampling of regulatory parts
for control of various biological processes involved in gene
expression.
Another approach, based on well-studied natural sys-
tems [26], was recently demonstrated by Dueber et al. to
complement these methods. This elegant approach uses
protein scaﬀolds that bear modular interaction domains to
physically link pathway enzymes that have been tagged with
theappropriatecorrespondingpeptideligands[27].Notonly
does enzyme colocalization limit the loss of intermediates
to competing pathways, it also enables the direct control
of metabolic ﬂux by adjusting the number of interaction
domains on the scaﬀold thereby adjusting the enzyme
complex composition.
Using a synthetic biology approach, the design of DNA
sequences encoding metabolic pathways (e.g., operons)
should be relatively straightforward. However, the prereq-
uisite collection of modular genetic parts has not yet been
developed, but progress has been made [28]. Synthetic
scaﬀolds and well-characterized families of regulatory parts
have emerged as powerful tools for engineering metabolism
by providing rational methodologies for coordinating con-
trol of multigene expression as well as decoupling pathway
design from construction. This approach begins to solve the
“impedanceproblem”byprovidingcomponentvariantswith
covering a range of input/output transfer functions, allowing
pathway tenability [29]. Pathway design should not overlook
the fact that exogenous pathways interact with native cellular
components and have their own speciﬁc energy require-
ments. Therefore, modifying endogenous gene expression
(e.g., gene knockouts, knockdowns, overexpression) may be
necessary in addition to balancing cofactor ﬂuxes (e.g., ATP,
NADH) and installing membrane transporters [30]. Figure 2
illustrates how well-characterized parts can be composited to
form functional devices or modules that can then be used to
build complex systems, including metabolic pathways.
3.Synthesis
Just as cars are routinely built from modular components in
assembly lines, rapid, modularized construction of micro-
bial chemical factories is on the horizon. Enabling this
manufacturing process is DNA synthesis technology, the
chemical fabrication of gene- and even genome-length DNA
molecules. For example, putative genes identiﬁed compu-
tationally in a metagenomics study need not be isolated
and cloned; the sequence information can be outsourced to
synthesis companies as Bayer et al. recently reported [31].
However, protocols exist to synthesize DNA in laboratories
using common equipment and techniques [32]. This capa-
bility opens many opportunities for metabolic engineers.
First of all, the convenience of this approach over traditional
cloning allows for the systematic generation of genetic part
variants such as promoter libraries (see Section 2). Secondly,
it provides a practical way for eliminating restriction sites
or undesirable RNA secondary structures and to codon
optimize genes for the expression in heterologous hosts.
Thirdly and perhaps most importantly, the generation of
biological building blocks will allow for the decoupling of
construction from design.
3.1. Parts. Generating genetic parts is as easy as emailing
the part’s nucleotide sequence to a DNA synthesis company
such as DNA2.0, GENEART, or Genscript. Depending on
the length and complexity of the part, it could take as
little as a week to synthesize and ship. Although synthesis
technology is available for individual laboratories, the time
and money required for equipment upkeep may not make
investment worthwhile, especially with commercial synthesis
prices steadily dropping. Still, the cost of DNA synthesis
is relatively high and can be a prohibitive factor for some
projects. It is anticipated that DNA synthesis technology4 Journal of Biomedicine and Biotechnology
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Figure 2: C a r t o o no fa ne n g i n e e r e dc e l l . Four distinct strategies have been combined to illustrate a synthetic biology approach to metabolic
engineering. The engineered pathway is encoded by a synthetic operon designed from standard parts/components including tunable
intergenicregions(TIGRs)thatprovidediﬀerentialcontrolovermRNAstability[41].Anupstreamdevice/module,atranscriptionalmodular
ANDgateactsasamasterregulatorbyrequiringtwoseparateinputstoturnonexpressionofthepathway[15].Theenzymeshavebeentagged
with a peptide ligand that binds them to a synthetic protein scaﬀold, forming a complex of colocalized pathway enzymes [27]. The central
metabolism of the host/chassis has been modiﬁed to interface with the engineered system/network, providing a suﬃcient ﬂux of necessary
precursors and cofactors as well as increased transporters to facilitate product secretion [7]. This image was generated in TinkerCell.
will follow in the footsteps of DNA sequencing technology
where research and improvements have decreased costs by
orders of magnitude. Czar et al. provide an excellent review
of synthesis technologies and strategies, including those that
enable in-house synthesis [33].
3.2. Pathways. The ability to make large changes to DNA
molecules has resulted in standardized methods for assem-
bling basic genetic parts into larger composite devices, which
facilitate part-sharing and faster system-level construction.
For example, the Registry of Standard Biological Parts sup-
ports the use of the BioBrick methodology to assemble parts
into devices and devices into systems. The restriction sites
ﬂank BioBrick parts (two serve as the preﬁx and the other
two as the suﬃx) allowing for restriction-ligation all the
while maintaining the same restriction sites. A standardized
assembly method, 3A BioBrick assembly, enables a three-
way ligation of two insert parts into a plasmid backbone and
eliminates the need to gel-purify digested parts and plasmid
backbones [11]. This approach can be automated using
programmable liquid-handling robots, providing a scalable
assembly process that can be used to quickly build systems
from existing genetic components. In this respect, high-
throughput pathway assembly is more easily implemented in
individual laboratories than de novo DNA part synthesis, but
there remains the option to outsource this aspect of synthesis
through commercial avenues as well.
Other approaches based on type II restriction enzymes,
such as Golden Gate Shuﬄing, provide ways to assemble
many more components together in one step [45]. A similar
one-step assembly approach, circular polymerase extension
cloning (CPEC), avoids the need for restriction-ligation or
single-stranded homologous recombination altogether. This
scalable, sequence-independent cloning technology works
by extending overlapping sequences between the part and
the plasmid backbone (e.g., BioBrick preﬁx and suﬃx),
just as polymerase extension occurs in PCR, resulting in a
complete circular plasmid [46]. Not only is this useful for
cloning single genes, but also for assembling parts into a
larger sequences encoding entire metabolic pathways and for
generating combinatorial part libraries.
Multiplex automated genome engineering (MAGE) was
recently introduced as another scalable, combinatorial
method for producing large-scale genomic diversity [47].
This approach makes chromosomal modiﬁcation easier by
simultaneouslymutatingtargetsitesacrossthechromosome.
In this method, a pool of degenerate oligonucleotides that
target speciﬁc genomic sites is cyclically introduced into
variouscellswithinthepopulation,whichgeneratesdiversity
across the population. MAGE was used to modify twenty
four genetic parts in the DXP pathway, including ribosomal
binding sites and enzyme coding sequences for tuning
expression levels and knocking out gene function. This
strategyresultedinaﬁvefoldincreaseinlycopeneproduction
in only three days, demonstrating a practical alternative to
encoding pathways on plasmids that often require many
iterations of testing and optimization.
Plasmid-based expression and chromosomal integration
are the two common vehicles for implementing synthetic
metabolic pathways and each method has its advantages,
described in an excellent review on gene-expression toolsJournal of Biomedicine and Biotechnology 5
Table 1: Compilation of biological controllers.
Biological process Genetic part or mechanism
Replication Replication origin (copy number) [34]
Transcription
Initation RNA polymerase [35], transcription factors [36], speciﬁcity factors [37], promoters [38],
enhancers, operator-regulator pairs [39], methylation
Elongation RNA polymerase [35], insulators, terminators [40], attenuators
Processing Splice sites, polyA sites, TIGRs [41]
Posttranscription
Degradation TIGRs [41], stabilizers, RNase sites [42]
Translation
Initiation Ribosome-RBS pairs [43], Riboregulators, Riboswitches, Ribozymes, Antisense RNA, MicroRNA,
Small interfering RNA. For a review on RNA parts see [44].
Elongation Codon bias, rare codons, stop codon-supressors pairs [15]
Processing Chaperones
Posttranslational
Degradation Proteases
Localization Target sequences, anchor sequences, interaction domain-peptide ligand pairs [27]
[48]. Recently, a new long-term expression method called
chemically inducible chromosomal evolution (CIChE) was
presented as an alternative to existing methods [49]. CIChE
avoidscomplicationsassociatedwithplasmidreplicationand
segregation, and can be used to integrate multiple copies of
genes(upto40copiesdemonstrated)intothegenome.These
techniques, coupled with in vivo strategies for assembling
genetic parts into systems encoding metabolic pathways
[50–52] and large-scale (several hundred kilobases) in vitro
assembly methods [53], will provide technical platforms
for the rapid synthesis of parts and subsequent pathways.
On a larger scale, bacterial genome transplantation and the
chemical synthesis of a natural bacterial genome have been
demonstrated [54, 55].
4.Analysis
Cells are not unlike computers in that they process input
information to realize output functions. A cell’s genome
can therefore be thought of as an operating system (OS)
and, similarly, engineered operons encoding metabolic path-
ways as individual programs that are built from well-
characterized, modular parts (the equivalent of a function in
computer science terms). A twist on this analogy is that there
already exists a large pool of parts and pathways in natural
and synthetic biological systems and we are collectively
learning their biological function through biochemical and
bioinformatic analyses. Therefore, before metabolic path-
ways can be rationally designed and constructed, the genetic
parts from which the pathways are built must be carefully
characterized.
4.1. Parts. With the capability to synthesize biological parts,
it is possible to use molecular-level controls to study and
analyze each part [56]. One of the major stumbling blocks
for the development of well-characertized parts is ﬁguring
out exactly what parameters should be measured and how.
Although made from ﬁve basic parts, the well-characterized
BioBrick signaling device BBa F2620 developed by Canton
et al. provided the ﬁrst example of what can be measured
and a possible standard documentation format—a datasheet
(see Canton et al. [57]f o rad e t a i l e de x a m p l eo fad a t a s h e e t ) .
The device’s performance characteristics, including input
compatibility,reliability,andtranscriptionaloutputdemand,
are neatly summarized. Datasheets may facilitate rapid
widespread adoption of synthetic biological parts, devices,
and systems if they include relevant information that is
available to the community [58].
Recent work toward characterizing promoters demon-
strates the utility of measuring the relative strengths of
promoters in a library as they are built [12]. A separate eﬀort
by Kelly et al. has proposed a promoter reference standard, a
ﬂuoresense-dependent measurement kit and a measurement
unit used to report promoter activity as an attempt to nor-
malize absolute measurements taken by various instruments
under various conditions [59] .T h ec o n c e p t u a lf r a m e w o r k
developedforpromotermeasurementcouldeasilybeapplied
to other genetic parts such as RBSs and transcriptional
terminators. However, these tools will only be beneﬁcial if
they are supported and adopted by the community.
4.2. Pathways. Although well-characterized parts will dras-
tically improve metabolic engineering eﬀorts, there will
always be a need for debugging tools and troubleshooting
methods. Systems biology provides a framework for analyz-
ing metabolic pathway performance and identifying possi-
ble solutions. Integrating high-throughput global measure-
ments (i.e., transcriptomics, proteomics, metabolomics, and
ﬂuxomics) and computational tools (see Section 5)o ﬀers
unprecedented understanding of how engineered pathways
aﬀectcellphysiologyandviceversaacrosstheentirecell[60].
Thiskindofanalysiscanbeusedtoidentifybottlenecksinthe6 Journal of Biomedicine and Biotechnology
pathway as well as detrimental side eﬀects that may not have
been obvious at the initial design stage [61].
Forexample,Kizeretal.usedtransciptionalandmetabo-
lite proﬁling to determine the biochemical interactions
of an engineered pathway and the endogenous metabolic
network [62]. In this work, they were not only able to
identify the bottleneck that resulted in toxic accumulation
of a pathway intermediate, but also the mechanism by
which the accumulated metabolite inhibits cellular growth—
and a way to overcome the problem. Using a system
biology analytical approach, metabolic engineers are able
to intelligently modulate synthetic pathway behavior if
the measured performance does not meet speciﬁcations.
Furthermore,thesyntheticbiologyframeworkshouldenable
therationalforward-engineeringofpathwaysinamoreplug-
and-play fashion and signiﬁcantly decrease the time spent on
debugging the genetic programs used to encode metabolic
function.
5. Modeling
Highly complex electrical circuits are able to be designed
with ease because of the existence of computer-aided
design (CAD) software. This technology is dependent on
the high-ﬁdelity virtual representation of physical circuit
componentry, which necessitates an accurate mathematical
model of each component (e.g., transistors, capacitors)
based on a deep understanding of the physics involved.
Once the fundamental physics of genetic part behavior is
understood, then parts can be designed to be insulated
from each other. Subsequently, abstract design based on
standard biological models would be possible, allowing CAD
of intricate metabolic pathways and regulatory networks.
While this is the ideal, there are a variety of modeling
approaches being applied to biology that have various
strengths and weaknesses leaving a consolidated, standard
modeling approach something to strive for in the future.
5.1. Parts. At the part-level, it is possible to develop highly
detailed, quantitative, dynamic models when considering a
single or small number of parts. The software tool ProMoT
was developed for modeling parts with ordinary diﬀerential
equations (ODEs) and enabling interfacing by quantifying
the exchange of biological signals (i.e., RNA polymerases,
ribosomes, transcription factors and environmental stim-
uli) between parts [63]. In a similar spirit, SBML- and
CellML-basedmodelsofgeneticpartsandwell-characterized
modules have been proposed for establishing a registry for
standard biological models [64, 65]. Standard, quantitative
models of genetic parts would allow biological engineers
to seamlessly integrate the design process with modeling,
enabling simulation of engineered systems prior to actual
construction (see design/model loop in Figure 1).
5.2. Pathways. As the scale of the system to be modeled
increases from a single pathway to all pathways within
an organism, more attention must be given to selecting a
modeling approach as the quality of simulation results can
vary simply due to the practical limitations imposed by
the increasing number of variables. It is anticipated that
as synthetic biology and modeling methods progress, the
line between design and modeling will be blurred. This
will condense the workﬂow into the common design-build-
test engineering cycle. A variety of CAD tools are emerging
to make this happen [66, 67]. Other computational tools
are being developed to make novel pathway design a high-
throughput process. From Metabolite to Metabolite (FMM)
is a web-based tool that constructs a variety of possible
enzymatic pathways from an input metabolite to an output
metabolite, both of which are provided by the user [68].
This saves a large amount of time spent searching through
the databases for relevant enzymes used in engineered path-
ways. Although not automated, the Retro-Biosynthesis Tool
(ReBiT) provides access to a searchable database of enzyme-
catalyzed reactions categorized by the relevant functional
groups of the reactants and products involved in the reaction
[69]. ReBiT returns a list of enzymes capable of consuming
or generating any user-deﬁned functional group, which is
particularly helpful for designing novel metabolic pathways
(i.e., nonnatural).
Although these tools will facilitate the design of engi-
neered systems, they will also need to take into account
connectivity with the existing cellular network. At this point,
even the most well-understood model microorganisms like
E. coli and S. cerevisiae are far from being completely
modeled [70, 71]. Therefore, interfacing engineered path-
ways with natural networks remains a diﬃcult task [72].
However, existing metabolic models, when combined with
powerful CAD tools to develop novel biological systems,
will streamline the metabolic engineering process. Current
genome-scale metabolic models are developed by deriving
reaction list from genome annotation, reﬁned using litera-
ture information and experimental data, and probed using
constraint-based algorithms such as ﬂux balance analysis
(FBA)[73].Thismodeling approachshouldenabledecision-
making when it comes to choosing an appropriate microbe
to host a particular synthetic pathway and provide a means
of predicting the in-context consequences of heterologous
expression.
6.Perspectives
Genetically programming microbes to perform desired tasks
has great potential to transform modern biotechnology.
Signiﬁcant progress has already been made in implementing
novel biological functionality in microorganisms, including
complex sensing/actuation algorithms and genetic circuits
that count [74–77] .T h e s ea d v a n c e sh a v ei m p l i c a t i o n sf o r
metabolic engineering. For example, genetic circuits have
been engineered to control the transcription of an operon
that encodes enzymes and machinery necessary to manu-
facture and secrete recombinant spider silk monomers in
Salmonella [78]. As progress is made in synthetic biology to
develop well-characterized parts and increasingly complex
devices, the design, modeling, synthesis, and analysis of
synthetic metabolic pathways will become easier.Journal of Biomedicine and Biotechnology 7
In metabolic engineering, there is an implicit view
of cells as chemical factories. As such, it can be useful
to borrow conceptual frameworks from chemical engi-
neering. Chemical plants are built from components that
generally fall into one of three classes: unit operations
(e.g., mixers, reactors, separators), connectors (pipes, tanks),
and process controllers (measurement instruments, valves).
These component classes exist within cells, but need to
be further reﬁned so that they can be used at the level
of sophistication found in a chemical plant. In addition
to advancing metabolic control through regulation of gene
expression (e.g., engineered promoters, tunable intergenic
regions [41]) and enzyme colocalization (modular protein
scaﬀolds, or perhaps synthetic organelles), the enzymes
themselves (i.e., speciﬁcity, activity, and allostery) can be
modulated through directed evolution [79, 80]o rp e r h a p s
designed/redesigned computationally. In fact, a recent study
showed that swapping catalytic domains from three fungal
cellulases can produce chimeras with superior properties
[81]. Furthermore, engineered enzymes with novel catalytic
properties would enable nonnatural metabolic pathway
implementation. However, rationally engineering enzymes
remain diﬃcult and must be conducted on a case-by-case
basis.
Therefore, it would be advantageous for the metabolic
engineering community to work within the synthetic biol-
ogy framework and focus on generating and populat-
ing families of genetic parts that are scalable, measured,
and modeled. The simultaneous construction and char-
acterization of parts will lead to model-based design of
pathways in the future, just as complex electrical circuits
are built in silico from well-modeled components. High-
throughput screening technologies have become power-
ful platforms for quantifying component performance of
combinatorially-generated libraries [41]. Likewise, high-
throughput measurements provide insight about evolved
systems that have adapted to meet performance criteria
[82]. These approaches could be very useful in identifying
the genetic basis of the biological solution that evolution
has provided, a strategy commonly referred to as inverse
metabolic engineering [83]. The interplay of rational, com-
binatorial, and evolutionary approaches is crucial to the
continued elucidation of biological design principles, which
allow further forward-engineering of biological systems
[84].
In order to achieve the forward-engineering of systems-
level metabolism, the design, modeling, synthesis, and
analysis stages must incorporate shared standards in order
to eﬃciently work together. In particular, well-characterized,
oﬀ-the-shelf genetic components and computational models
of these components must be available for use within a
standard biological CAD tool. As models of components and
modules develop, metabolic engineers will be able to move
away from using the equivalent of biological machine code
(DNA bases: ATCGs) for design to using compiled biological
programs (genes and genetic circuits) that will enable faster
pathway design by reusing pieces of previously optimized
pathways. Similarly, characterization methods and standard
measurement units must be agreed on so that parts are
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Figure 3: Convergence of the diﬀerent realms of synthetic biology. In
addition to eﬀorts to reﬁne and characterize genetic parts based on
DNA, research on expanding the genetic code and implementing
biological processes in cell-free systems will likely integrate with
metabolic engineering projects in the future. Genome engineering
and synthetic genomics will enable the manufacture of customiz-
able minimal genomes. Alternatively, protocell engineering may
provide a non-biological chassis to house synthetic chemistry.
characterized as they are made in a way that is useful to the
community.
As already envisioned by a number of people [56, 61],
integration of synthetic biology and systems biology will
likely occur as both ﬁelds grow, eventually leading to tools
that can allow for true cellular-scale network and pathway
engineering. In many respects the ﬁelds of synthetic biology
and systems biology are perfect complements to each other
in regard to outlook and approach as we move toward whole-
cell engineering. While some overlap already exists between
the two ﬁelds, synthetic biology currently has signiﬁcant
strengths in the steps of biological design and synthesis
whereas systems biology has strengths in analysis and mod-
eling (Figure 1). To properly integrate the detailed, dynamic,
small-network components of synthetic biology with the
large-scale analyses and algorithms of systems biology, it will
be necessary to ensure that work in each ﬁeld is compatible
with work in the other ﬁeld. For example, large-scale systems
biology models will need to be able to incorporate dynamic
behaviordemonstratedbyconstructedsyntheticcircuits,and
synthetic circuits should be constructed and implemented to
have minimal cross-talk with existing cellular components.
One can imagine a time when design can happen at a large-
scalelevelusingsystemsbiologyalgorithms[85–87]followed
by molecular-level design using synthetic biology tools, de
novo synthesis of components and pathways, analysis of
results using high-throughput systems biology methods, and
a hybrid large-scale, dynamic model of the entire process.
As the ﬁeld of synthetic biology matures, various
branches of synthetic biology that were not discussed here8 Journal of Biomedicine and Biotechnology
will soon be relevant to implementing novel metabolism
in microbes (Figure 3). For example, a streamlined chassis
based on a minimal, refactored genome would simplify
host/system interactions and potentially minimize the eﬀect
of the metabolic burden the exogenous pathway would place
on the cell. Likewise, the concept of designer microbes with
engineered genomes could be realized by the developing area
of synthetic genomics, which is dependent on the continued
improvement in DNA synthesis technology. In the near
future, host strains that have been engineered to confer com-
plex phenotypes (e.g., solvent tolerance) using techniques
such global transcription machinery engineering (gTME)
mayprovideexcellentchassisforsyntheticmetabolicsystems
[37, 88]. Even so, recent successes in synthetic biology-
enabled metabolic pathway engineering in common lab
strains are very encouraging [31, 89–93]. Furthermore, work
done toward engineering microbial communities may pro-
vide an approach to industrial biosynthesis that is superior
to monocultures due to increased diversity and ﬂexibility
[94]. The future of this ﬁeld is extremely exciting and will
likely include rapid prototyping, testing, and debugging
of synthetic metabolism for the industrial-scale microbial
production of a wide variety of natural and novel chemicals
and materials.
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